• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comorbid Conditions in Patients With Metastatic Colorectal Cancer.转移性结直肠癌患者的合并症
World J Oncol. 2011 Oct;2(5):225-231. doi: 10.4021/wjon370e. Epub 2011 Oct 28.
2
Agreement between hospital discharge diagnosis codes and medical records to identify metastatic colorectal cancer and associated comorbidities in elderly patients.医院出院诊断编码与病历之间的一致性,以识别老年患者的转移性结直肠癌及相关合并症。
Rev Epidemiol Sante Publique. 2017 Aug;65(4):321-325. doi: 10.1016/j.respe.2017.03.132. Epub 2017 May 31.
3
Determining the cost of obesity and its common comorbidities from a commercial claims database.从商业理赔数据库确定肥胖症及其常见合并症的成本。
Clin Obes. 2014 Feb;4(1):53-8. doi: 10.1111/cob.12041. Epub 2013 Nov 22.
4
Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.错配修复缺陷转移性结直肠癌的结局:梅奥诊所的经验。
Oncologist. 2018 Sep;23(9):1083-1091. doi: 10.1634/theoncologist.2017-0289. Epub 2018 Apr 19.
5
Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data.初级保健中心心血管疾病患者的合并症:一项基于常规医疗保健数据的队列研究。
Br J Gen Pract. 2019 Jun;69(683):e398-e406. doi: 10.3399/bjgp19X702725. Epub 2019 May 7.
6
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.估算新诊断转移性结直肠癌患者的护理费用。
Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021.
7
The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.美国转移性结直肠癌治疗相关常见不良事件的经济负担。
J Med Econ. 2017 Jan;20(1):54-62. doi: 10.1080/13696998.2016.1225577. Epub 2016 Sep 7.
8
Risk Factors of QTc Prolongation in Women With Hormone Receptor‒positive/Human Epidermal Growth Factor Receptor 2‒negative Metastatic Breast Cancer: A Retrospective Analysis of Health Care Claims Data.激素受体阳性/人表皮生长因子受体 2 阴性转移性乳腺癌女性发生 QTc 延长的风险因素:医疗保健索赔数据的回顾性分析。
Clin Ther. 2019 Mar;41(3):494-504.e1. doi: 10.1016/j.clinthera.2019.01.012. Epub 2019 Feb 18.
9
Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.获得生物制剂与生存率提高的关联:南澳大利亚州(SA)转移性结直肠癌(mCRC)登记处的结果。
Acta Oncol. 2016;55(4):480-5. doi: 10.3109/0284186X.2015.1117135. Epub 2016 Feb 15.
10
Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study.新接受多发性骨髓瘤治疗患者的高血压发病率及风险:一项回顾性队列研究
BMC Cancer. 2016 Nov 22;16(1):912. doi: 10.1186/s12885-016-2955-0.

引用本文的文献

1
Age-related trends in the incidence of metastatic colorectal cancer from 2010 to 2019 in the USA.美国 2010 年至 2019 年转移性结直肠癌发病率的年龄相关趋势。
Future Oncol. 2024;20(16):1111-1121. doi: 10.2217/fon-2023-0376. Epub 2023 Sep 13.
2
Mini-review: Angiotensin- converting enzyme 1 (ACE1) and the impact for diseases such as Alzheimer's disease, sarcopenia, cancer, and COVID-19.综述:血管紧张素转换酶1(ACE1)及其对阿尔茨海默病、肌肉减少症、癌症和新冠肺炎等疾病的影响。
Front Aging. 2023 Jan 23;4:1117502. doi: 10.3389/fragi.2023.1117502. eCollection 2023.
3
Colon cancer laterality is associated with atherosclerosis and coronary artery disease.结肠癌的发病部位与动脉粥样硬化和冠状动脉疾病相关。
J Gastrointest Oncol. 2019 Feb;10(1):30-36. doi: 10.21037/jgo.2018.09.18.

本文引用的文献

1
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.随机、III 期临床试验:帕尼单抗联合氟尿嘧啶、亚叶酸钙和奥沙利铂(FOLFOX4)对比 FOLFOX4 一线治疗未经治疗的转移性结直肠癌患者:PRIME 研究。
J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.
2
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.一项比较帕尼单抗联合氟尿嘧啶、亚叶酸钙和伊立替康(FOLFIRI)与单独 FOLFIRI 二线治疗转移性结直肠癌患者的随机 III 期研究。
J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.
3
Does the timing of comorbidity affect colorectal cancer survival? A population based study.共病发生时间是否影响结直肠癌患者的生存?一项基于人群的研究。
Postgrad Med J. 2010 Feb;86(1012):73-8. doi: 10.1136/pgmj.2009.084566.
4
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
5
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.转移性结直肠癌患者生存率的提高与肝切除的采用及化疗的改善有关。
J Clin Oncol. 2009 Aug 1;27(22):3677-83. doi: 10.1200/JCO.2008.20.5278. Epub 2009 May 26.
6
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.西妥昔单抗与化疗联合作为转移性结直肠癌的初始治疗方案
N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
7
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.氟尿嘧啶、亚叶酸钙以及奥沙利铂联合或不联合西妥昔单抗用于转移性结直肠癌的一线治疗。
J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.
8
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.癌症患者使用血管生成抑制剂贝伐单抗发生静脉血栓栓塞的风险:一项荟萃分析。
JAMA. 2008 Nov 19;300(19):2277-85. doi: 10.1001/jama.2008.656.
9
Age, comorbidity, treatment decision and prognosis in lung cancer.肺癌的年龄、合并症、治疗决策与预后
Age Ageing. 2008 Nov;37(6):715-8. doi: 10.1093/ageing/afn226.
10
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.奥沙利铂与氟嘧啶方案联合或不联合贝伐单抗作为转移性结直肠癌一线治疗的安全性和有效性:TREE研究结果
J Clin Oncol. 2008 Jul 20;26(21):3523-9. doi: 10.1200/JCO.2007.15.4138.

转移性结直肠癌患者的合并症

Comorbid Conditions in Patients With Metastatic Colorectal Cancer.

作者信息

Fu Alex Z, Zhao Zhongyun, Gao Sue, Barber Beth, Liu Gordon G

机构信息

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.

Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.

出版信息

World J Oncol. 2011 Oct;2(5):225-231. doi: 10.4021/wjon370e. Epub 2011 Oct 28.

DOI:10.4021/wjon370e
PMID:29147252
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5649683/
Abstract

BACKGROUND

Patients with metastatic colorectal cancer (mCRC) often have other medical conditions that may impact treatment decisions, prognoses and quality of care. We aimed to assess co-existing medical conditions in the mCRC patient population. This retrospective cohort study used linked medical and pharmacy claims data from two US-based Medstat MarketScan claims databases and identified patients with newly diagnosed mCRC between January 2005 and June 2008.

METHODS

Patient data were analyzed for comorbid conditions and medication use in the year prior to diagnosis of mCRC. Univariate analyses were conducted to compare the comorbid conditions between patients aged ≥ 65 and < 65 years old. In total, 12 648 patients aged ≥ 18 years were identified. The study was evenly populated by gender and age above and below 65, and most patients had a primary diagnosis of colon cancer (70.1%).

RESULTS

The most prevalent comorbidity was cardiovascular disease (CVD) (55.7% of patients) including hypertension (40.8%), cardiac dysrhythmia (14.2%), coronary artery disease (13.5%), congestive heart failure (7.2%) and arterial and venous thromboembolism (6.2% and 4.6%, respectively). Most comorbidities were significantly more prevalent in patients ≥ 65 years of age, particularly with respect to CVD (67.9% versus 42.5%, respectively; P < 0.0001). Additionally, nearly half (49.7%) of the patients received antihypertensive agents and many patients were prescribed more than one class of medications prior to mCRC diagnosis.

CONCLUSIONS

Comorbid medical conditions, particularly CVDs, are common in patients with mCRC, which could increase the complexity of patient management. This should be a consideration integral to the selection of the most appropriate treatment for individual patients.

摘要

背景

转移性结直肠癌(mCRC)患者通常还患有其他疾病,这些疾病可能会影响治疗决策、预后和医疗质量。我们旨在评估mCRC患者群体中并存的疾病情况。这项回顾性队列研究使用了来自美国两个基于Medstat MarketScan理赔数据库的关联医疗和药房理赔数据,确定了2005年1月至2008年6月期间新诊断为mCRC的患者。

方法

分析患者在mCRC诊断前一年的合并症情况和用药情况。进行单因素分析以比较年龄≥65岁和<65岁患者之间的合并症情况。总共确定了12648名年龄≥18岁的患者。该研究在性别以及65岁上下的年龄分布上较为均衡,大多数患者的原发性诊断为结肠癌(70.1%)。

结果

最常见的合并症是心血管疾病(CVD)(占患者的55.7%),包括高血压(40.8%)、心律失常(14.2%)、冠状动脉疾病(13.5%)、充血性心力衰竭(7.2%)以及动脉和静脉血栓栓塞(分别为6.2%和4.6%)。大多数合并症在≥65岁的患者中更为普遍,尤其是CVD(分别为67.9%和42.5%;P<0.0001)。此外,近一半(49.7%)的患者接受了抗高血压药物治疗,并且许多患者在mCRC诊断前被开具了不止一类药物。

结论

合并的疾病情况,尤其是CVD,在mCRC患者中很常见,这可能会增加患者管理的复杂性。这应成为为个体患者选择最合适治疗方法时不可或缺的考虑因素。